U.S. President Donald Trump announced on Wednesday that tariffs on imported generic drugs will increase to 200% by 2028, with a phased approach starting August 1, 2026. This policy aims to encourage pharmaceutical companies to relocate their manufacturing to the United States, particularly impacting India, the largest exporter of generic drugs to the U.S.
Tariff Timeline
According to Trump's statement on Truth Social, generic drugs will remain tariff-free for the first two years, after which a 100% tariff will be imposed for one year, followed by the 200% tariff. Trump emphasized that this initiative is part of a broader strategy to
reshore Generic Pharmaceutical Production into America
and penalize companies that do not establish manufacturing plants in the U.S. during this transition period.
Impact on Indian Exports
In 2025, India exported approximately $9.7 billion worth of pharmaceuticals to the U.S., representing 38% of its total global pharma exports of $25.8 billion, according to a report by the Global Trade Research Initiative. The U.S. Food and Drug Administration noted that generic drugs account for over 90% of prescriptions filled in the country. Trump's announcement builds on previous tariffs imposed on branded pharmaceuticals, which were introduced in April 2026, requiring manufacturers to agree to government-backed pricing arrangements or shift production to the U.S.
Related coverage: Trump Orders 50% Tariffs on Select Canadian Products, Trump imposes 50% tariffs on select Canadian goods.
The impending tariffs could significantly affect the pharmaceutical sector, particularly impacting Indian drug manufacturers who rely heavily on the U.S. market. The introduction of these tariffs may lead to higher prices for generic drugs in the U.S., potentially influencing healthcare costs and access for consumers.
Watch for further developments as companies respond to the new tariff structure and any potential negotiations regarding manufacturing commitments.